19
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Viersprong Institute for studies on Personality Disorders (VISPD) Personality Disorders (VISPD) [email protected] +31 164 632200 Department of Medical Psychology & Department of Medical Psychology & Psychotherapy, Erasmus University Medical Psychotherapy, Erasmus University Medical Center Center

Interactive Introduction cost effectiveness

Embed Size (px)

DESCRIPTION

Interactive Introduction cost effectiveness. Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD) [email protected] +31 164 632200 Department of Medical Psychology & Psychotherapy, Erasmus University Medical Center. New cancer therapy. - PowerPoint PPT Presentation

Citation preview

Page 1: Interactive Introduction  cost effectiveness

Interactive Introduction cost effectiveness

Jan J. v. Busschbach, Ph.DJan J. v. Busschbach, Ph.DViersprong Institute for studies on Personality Viersprong Institute for studies on Personality Disorders (VISPD)Disorders (VISPD)

[email protected]+31 164 632200

Department of Medical Psychology & Department of Medical Psychology & Psychotherapy, Erasmus University Medical Center Psychotherapy, Erasmus University Medical Center

Page 2: Interactive Introduction  cost effectiveness

2

New cancer therapy

Symptoms Drug X Drug Y

Survival days 300 400Days sick of chemotherapy 10 150Days sick of disease 100 30TWiST 190 220

Page 3: Interactive Introduction  cost effectiveness

3

Time Without Symptoms of disease and subjective Toxic effects of treatment

• TWiST– Developed by Richard Gelber (statistician)

• In search for a typical “cancer” problem– Often prolonged life but also a reductions in

quality of life• At the beginning (side effects)• At the end

– Only count the days without symptoms of disease and subjective toxic effects of the treatment

Page 4: Interactive Introduction  cost effectiveness

4

Fit new therapy in fixed budget

• 50 patients each year (per hospital) – Drug x: 50 x euro 1.750 = euro 87.500– Drug y: 50 x euro 2.000 = euro 100.000

• Drug budget for x or y = euro 50.000– Number of patient

• Drug x: euro 50.000 / 1.750 = 28.5 patients• Drug y: euro 50.000 / 2.000 = 25.0 patients

– Survival in days• Drug x: 28.5 patients x 300 days = 8.550 days• Drug y: 25.0 patients x 400 days = 10.000 days

– Survival in TWiST• Drug x: 28.5 patients x 190 TWiST = 5.415 days• Drug y: 25.0 patients x 220 TWiST = 5.500 days

Page 5: Interactive Introduction  cost effectiveness

5

TWiST: ignores differences in quality of life

• TWiST– Healthy = 1– Sick (dead) = 0

• There is more to life than sick/health– Make intermediate values– Q-TWiST

• Quality of life adjusted adjusted TWiST• How to scale quality of life?

0.0 Q

uality of lif

e 1

.0

Page 6: Interactive Introduction  cost effectiveness

6

Value a health state

• Wheelchair– Some problems in walking about– Some problems washing or dressing– Some problems with performing usual activities– Some pain or discomfort– No psychosocial problems

Page 7: Interactive Introduction  cost effectiveness

7

Time Trade-Off

• TTO• Wheelchair

– With a life expectancy: 50 years• How many years would you trade-off for a cure?

– Max. trade-off is 10 years• QALY(wheel) = QALY(healthy)

– Y * V(wheel) = Y * V(healthy)– 50 V(wheel) = 40 * 1

• V(wheel) = .80

Page 8: Interactive Introduction  cost effectiveness

8

EuroQol EQ-5D: of the shelf QALY value

• MOBILITY– I have no problems in walking about – I have some problems in walking about – I am confined to bed

• SELF-CARE– I have no problems with self-care – I have some problems washing or dressing myself – I am unable to wash or dress myself

• USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)

– I have no problems with performing my usual activities – I have some problems with performing my usual

activities – I am unable to perform my usual activities

• PAIN/DISCOMFORT– I have no pain or discomfort – I have moderate pain or discomfort – I have extreme pain or discomfort

• ANXIETY/DEPRESSION– I am not anxious or depressed – I am moderately anxious or depressed – I am extremely anxious or depressed

Page 9: Interactive Introduction  cost effectiveness

9

In health economics: Q-TWiST = QALY

• Count life years• Value (V) quality of life (Q)

– V(Q) = [0..1] • 1 = Healthy• 0 = Dead

– One dimension• Adjusted life years (Y) for value quality of life

– QALY = Y * V(Q)• Y: numbers of life years• Q: health state• V(Q): the value of health state Q

• Also called “utility analysis”

Page 10: Interactive Introduction  cost effectiveness

10

• A new wheelchair for elderly (iBOT)• Special post natal care

Which health care program is the most cost-effective?

Page 11: Interactive Introduction  cost effectiveness

11

Which health care program is the most cost-effective?

• A new wheelchair for elderly– Increases quality of life = 0.1 – 10 years benefit– Extra costs: $ 3,000 per life year– QALY = Y x V(Q) = 10 x 0.1 = 1 QALY– Costs are 10 x $3,000 = $30,000– Cost/QALY = 30,000/QALY

• Special post natal care– Quality of life = 0.8– 35 year– Costs are $250,000– QALY = 35 x 0.8 = 28 QALY– Cost/QALY = 8,929/QALY

Page 12: Interactive Introduction  cost effectiveness

12

Effect psychotherapy

0.5

0.6

0.7

0.8

0.9

1.0

Intake 1 year after 2 years

EQ

-5D

soc

ial v

alue

s

Clinic 12 months

Clinic 6 months

Clinic 3 months(STIP)Out-patient clinic

Page 13: Interactive Introduction  cost effectiveness

13

Example STIP

• Short-Term Inpatient Psychotherapy• Cost price

– Per patient day: € 210.34– 3 mouths = 91.3 day– 91.3 x 210 = € 19,194.53

• Includes overhead– Buildings, administration, etc

• Excluding– Savings elsewhere in health care system

• Effect– Assume quality of life increase of 0.25– Over 10 year

• Cost / QALY– 19,194.54 / (10 x 0.25) = € 7,677.41

Although gold standard…

Cost per QALY of

psychotherapy have never been

published

Page 14: Interactive Introduction  cost effectiveness

14

QALY league table

Intervention $ / QALY GM-CSF in elderly with leukemia 235,958

EPO in dialysis patients 139,623

Lung transplantation 100,957

End stage renal disease management 53,513

Heart transplantation 46,775

Didronel in osteoporosis 32,047

PTA with Stent 17,889

STIP: Short-term inpatient psychotherapy 7,677

Breast cancer screening 5,147

Viagra 5,097

Treatment of congenital anorectal malformations 2,778

Page 15: Interactive Introduction  cost effectiveness

15

1.0

0.0A B C

Util

ity o

f Hea

l th

Egalitarian Concerns:Burden of disease

Page 16: Interactive Introduction  cost effectiveness

16

Implications shifting threshold

• QALY are weighted• Weighted QALYs are maximized

– Health is no longer the only thing maximized• Health status population will drop• Differences in health will drop

– Egalitarian consideration are incorporated• Burden of disease becomes a criteria

– Equity

Page 17: Interactive Introduction  cost effectiveness

17

CE-ratio by equity

Page 18: Interactive Introduction  cost effectiveness

18

Burden of disease based on STEP-data (N = 641)

0.0

0.2

0.4

0.6

0.8

1.0

Page 19: Interactive Introduction  cost effectiveness

19

Conclusion

• Introduce state-of-the-art cost effectiveness studies– Measure costs and outcome

• Suitable for cost effectiveness studies• According to guidelines

• Establish burden of disease– State-of-the-art quality of life research

• Use an active approach on budget constrains– Anticipate on policy arguments– Look for beyond own discipline